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Abstract
Histone deacetylase inhibitors (HDACi) induce tumor cell cycle arrest and/or apoptosis, and some of them are currently used in cancer ther-
apy. Recently, we described a series of powerful HDACi characterized by a 1,4-benzodiazepine (BDZ) ring hybridized with a linear alkyl chain
bearing a hydroxamate function as Zn-chelating group. Here, we explored the anti-leukaemic properties of three novel hybrids, namely
the chiral compounds (S)-2 and (R)-2, and their non-chiral analogue 4, which were first comparatively tested in promyelocytic NB4 cells.
(S)-2 and partially 4 – but not (R)-2 – caused G0/G1 cell-cycle arrest by up-regulating cyclin G2 and p21 expression and down-regulating
cyclin D2 expression, and also apoptosis as assessed by cell morphology and cytofluorimetric assay, histone H2AX phosphorylation and
PARP cleavage. Notably, these events were partly prevented by an anti-oxidant. Moreover, novel HDACi prompted p53 and -tubulin acety-
lation and, consistently, inhibited HDAC1 and 6 activity. The rank order of potency was (S)-2  4  (R)-2, reflecting that of other biologi-
cal assays and addressing (S)-2 as the most effective compound capable of triggering apoptosis in various acute myeloid leukaemia (AML)
cell lines and blasts from patients with different AML subtypes. Importantly, (S)-2 was safe in mice (up to 150 mg/kg/week) as determined
by liver, spleen, kidney and bone marrow histopathology; and displayed negligible affinity for peripheral/central BDZ-receptors. Overall, the
BDZ-hydroxamate (S)-2 showed to be a low-toxic HDACi with powerful anti-proliferative and pro-apototic activities towards different cul-
tured and primary AML cells, and therefore of clinical interest to support conventional anti-leukaemic therapy.
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Introduction
The balance between histone acetyl-transferase (HATs) and his-
tone deacetylase (HDACs) activities is known to play a significant
role in chromatin remodeling and epigenetic regulation of gene
expression in several diseases. In cancer, HATs are often function-
ally inactivated or mutated while over-expression of many HDACs
has been reported [1–4]. Therefore, HDACs have become attrac-
tive chemotherapy targets for a range of structurally diverse natu-
ral or synthetic agents – hydroxamates, cyclic peptides, elec-
trophilic ketones, short-chain fatty acids and benzamides [5, 6] –
acting as HDAC inhibitors (HDACi). These epigenetic agents are
known to induce: (i ) acetylation of histones – that is functional to
a chromatin relaxed status and proper interaction of transcription
factors to DNA elements – as well as of nonhistone proteins [7];
and (ii ) cell growth arrest and/or apoptosis in several cancer mod-
els through the activation of multiple pathways including genera-
tion of reactive oxygen species (ROS), inhibition of angiogenesis
and increase in autophagy [5]. However, regardless of specific
action mechanisms of HDACi, their greater activity in cancer cells
relative to normal cells has widely been recognized [4, 8] and
some of them are currently employed in the clinic as monotherapy
and/or in combination with conventional anti-neoplastic agents 
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[5, 9]. Vorinostat is the first HDACi approved by the FDA for treat-
ment of cutaneous T-cell lymphoma [5, 10], but also MS-275,
romidepsin and valproic acid are now in phases I/III of clinical 
trials to treat different types of human cancers.
Recently, we reported and preliminarily assayed in acute
promyelocytic leukaemia NB4 cells a wide series of powerful
HDACi characterized by a 1,4-benzodiazepine ring (BDZ) used as
the cap and joined, through an amide function or a triple bond con-
nection unit, to a linear alkyl chain carrying a hydroxamate moiety
as the Zn-chelating group [11]. The present study focuses on
three novel HDACis, namely the chiral compounds (S)-2 and 
(R)-2, and their non-chiral analogue 4, which have comparatively
been tested for their ability to induce growth arrest and apoptosis
in NB4 cells, and to target specific HDAC isoforms. Taken together,
our results point to (S)-2 as the most effective among the three
hybrids to trigger apoptosis in various acute myeloid leukaemia
(AML) cell lines and blasts from patients with different AML sub-
types [12]. Furthermore, (S)-2 was safe for normal CD-1 mice up
to 150 mg/kg/week along with acute toxicity experiments as
revealed by histopathology of explanted organs and showed no
affinity for central (CBR) and peripheral BDZ receptors (PBR).
These findings confirm the anti-leukaemic efficacy and safety of
(S)-2, which may offer interesting clinical opportunities to treat
AML and, possibly, other types of malignancies.
Materials and methods
Cell lines, blasts and culture conditions
Different AML cell lines, including KG1a, Kasumi, HL-60, ATRA-sensitive
NB4 and ATRA-resistant NB4-MR4, THP-1 and U937 were employed and
cultured as previously reported [13]. Blasts from bone marrow aspirate
and/or peripheral blood of newly diagnosed AML patients with M1-M4 sub-
types as well as peripheral mononuclear blood cells (PMBCs) from normal
subjects were obtained after informed consent and according to the
Hospital Committee Ethics guidelines (Helsinki declaration). Blasts and
PBMCs were isolated and cultured as described elsewhere [14].
Reagents
The 1,4-benzodiazepine ring (5-phenyl-1,3-dihydro-2-oxo-benzo[e][1,4]-
diazepine) was used as the cap of novel hydroxamic-based HDACi [11].
The chiral compounds (S)-2 and (R)-2, and their non-chiral analogue 4
(Fig. 1) were dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St
Louis, MO, USA), stored as 0.1 M stock solutions in the dark at room tem-
perature and added directly to the culture. The amount of DMSO used as
the vehicle did not interfere with drug biological activities. All other chem-
icals were reagent grade.
RNA extraction, RT-PCR and QRT-PCR experiments
For details on methodologies and the primers used see Supporting
Information (S1)
Cell extraction, SDS-PAGE and Western blotting
Harvested cells were resuspended in a lysis buffer (1 mM phenylmethyl-
sulfonyl fluoride, 1% Triton X-100, 40 mM Tris–HCl pH 8.0, 150 mM NaCl)
containing a cocktail of proteinase inhibitors (Calbiochem, Merck KGaA,
Darmstadt, Germany) and treated by sonication (Microson XL-2000,
Misonix, Farmingdale, NY, USA). Proteins were assayed by the BCA Protein
Assay (Thermo Scientific, Rockford, IL, USA), analysed by SDS-PAGE and
Western blotting as reported elsewhere [13]. Membranes were probed with
primary antibodies against p53 (Abcam, Cambridge, UK); acetyl-H3,
acetyl-H4, acetyl-p53 and H4 (Upstate Biotechnology, Millipore, Bilerica,
MA, USA); PARP, -H2AX, H2AX, H3 (Cell Signaling Technology, Danvers,
MA. USA); -tubulin and acetylated -tubulin (Sigma-Aldrich, ST. Louis,
MO, USA). Suitable peroxidase-conjugated IgG preparations (Sigma-
Aldrich) were used as secondary antibodies; the ECL procedure was
employed for development.
Cell cycle analysis and determination of apoptosis
Cell cycle distribution was measured by using the propidium iodide (PI)-
hypotonic citrate method with a FACScan flow cytometer (Becton-
Dickinson, San Jose, CA, USA) [15]. Apoptosis was assessed either cyto-
fluorimetrically by using the Annexin-V-Fluos/PI assay (Roche Molecular
Biochemicals, Mannheim, Germany), or morphologically by examining
May-Grünwald/Giemsa stained cytosmears as reported elsewhere [13].
Determination of HDAC enzyme activity
The sensitivity of human recombinant HDAC1 and 6 enzymes to novel
HDACi was assessed by fluorimetric assays (Supporting Information, S2)
using the Boc-L-Lys(-acetyl)-MCA and the Boc-L-Lys(-trifluoroacetyl)-
MCA as the substrates [16].
Acute toxicity experiments
Different groups of CD-1 mice were collected and treated with either DMSO
as the vehicle or increasing amounts of (S)-2 and 4 given i.p. up to 
Fig. 1 Chemical structures of compounds used in this work. The numbers
labelling the compounds are the same as in ref. [11].
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150 mg/Kg (about 5 mg/mouse). Animals were sacrificed after 7 days for
histopathological evaluation of liver, kidney, spleen and bone marrow
(Supporting Information, S3).
Binding experiments
The relative affinities of rac-7 (as an example of the cap in its racemic
form), (S)-2, (R)-2, and 4 for CBR and PBR, respectively were assessed
[17, 18] and evaluated quantitatively with the weighted least-squares iter-
ative curve fitting program LIGAND [19] (Supporting Information, S4).
Statistical analysis
Other data were analysed by Student’s t-test. Significance was determined
by analysis of variance followed by Newman-Keuls post-tests using Prism
version 4.0 (GraphPad software, San Diego, CA, USA).
Results
Compounds used in this study
The rationale for generating novel BDZ-hydroxamate hybrids with
HDACi activity has been previously described [11] and the molec-
ular structures of compounds used in this work were reported
(Fig. 1). Briefly, the 1,4-benzodiazepine ring containing a chiral
centre in position 3 was used as the cap and joined through a
triple bond connection unit to a linear alkyl chain ending with a
hydroxamic function, partially mimicking oxamflatin [20]. In this
way, the BDZ-hydroxamate enantiomers (S)-2 and (R)-2 as well as
their non-chiral analogue lacking the 3-methyl group on the cap
and indicated as compound 4 were obtained.
Effects of novel HDACi on NB4 cell growth 
and cell cycle distribution
BDZ-hybrids have already been reported to induce acetylation of
histone H3 and H4 in NB4 cells [11]. In the present work all three
novel HDACi were found to be able, though with different potency,
to inhibit cell growth in a dose- and time-dependent manner 
(Fig. 2A). (S)-2 and 4 were the more effective agents (IC50  0.41
and 0.98 M, respectively) after 72 hrs of treatment, while (R)-2
was much less active (IC50  3.81 M).
Cell cycle analysis at 24 hrs (Fig. 2B) showed that (S)-2 caused
a striking arrest of cells in G0/G1 (approximately 82% versus 34%
of control) and a marked decrease in S phase, while cell cycle pro-
files of (R)-2-treated and control cells virtually overlapped.
Compound 4 was less potent than (S)-2 in arresting cell growth
but, interestingly, led to a partial cell blockage in G2. These 
Fig. 2 Biological effects of (S)-2, (R)-2 and 
4 on NB4 cells. (A) Growth curves: NB4 cells
(110	5/ml) were incubated up to 96 hrs
without/with increasing concentrations of
either (S)-2, (R)-2 or 4. Cells densities were
evaluated daily with the aid of a Bürker
chamber and reported as results of a typical
experiment out of three. (B) Cell cycle 
analysis was performed on propidium iodide
(PI)-stained NB4 cells treated without/with 
2 M drugs for 24 hrs, by flow cytometry
(PI labelling, X-axis; total events, Y-axis). (C)
Cyclin D2, cyclin G2 and p21 mRNA levels
from cells treated without/with 2 M drugs
for 6, 15 and 24 hrs were measured by
quantitative reverse transcriptase poly-
merase chain reaction (RT-PCR; see
Supporting Information, S1). Columns and
bars were the means 
 SD of three separate
experiments and asterisks indicated the 
significant differences between treated and
untreated cells (*** P 0.001; * P 0.05).
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findings are consistent with molecular biology data showing that
at all the time points within 24 hrs (S)-2 and 4 were able to up-
regulate cyclin G2 and p21 expression, and down-regulate cyclin
D2 expression, whereas (R)-2 was nearly ineffective (Fig. 2C).
BDZ-hybrids (S)-2 and 4, but not (R)-2, 
induce apoptosis in NB4 cells
Pro-apoptotic efficacy of (S)-2 and 4, as measured by flow cytom-
etry after a 2-day treatment with 2.5 M, was high and accounted
for approximately 90% and 80% of cell population, respectively,
while (R)-2 did not alter cell viability relative to control (Fig. 3A,
top). Examination of stained cytosmears confirmed the massive
nuclear fragmentation in (S)-2-treated cultures that depicts a late
apoptotic stage, while cell shrinking, to suggest an early apoptotic
phase, was the predominant feature in 4-treated cultures (Fig. 3A,
bottom). Moreover, pro-apoptotic properties of (S)-2 and 4 were
also proven by the cleavage of poly(ADP-ribose)-polymerase
(PARP) as the ultimate target of the caspase cascade (Fig. 3B) and
producing to generate a fragment of approximately 89 kD and,
subsequently, by histone H2AX phosphorylation to yield -H2AX
(Fig. 3C) in response to drug-mediated DNA damage [21]; these
events did not occur in either untreated or (R)-2-treated cells.
Drugs induce acetylation of histone 
and nonhistone proteins and inhibit HDAC1 
and 6 enzymatic activity
Western blot analyses carried out on NB4 cells confirmed, as pre-
viously reported [11], that a 6-hr incubation with (S)-2 and 4
caused histone H3/H4 acetylation, while (R)-2 was definitely less
active (Fig. 4A). However, nonhistone proteins like -tubulin and
p53 also underwent drug-induced acetylation, as detected after 6-
hr and 24-hr treatment, respectively (Fig. 4B). Acetylated -tubu-
lin is a well-known substrate for the mainly cytoplasmic class IIb
enzyme HDAC6 [22] and acetylated p53 is a specific substrate for
the primarily nuclear class I enzyme HDAC1 [23], thus inferring
that these two isoforms were sensitive targets for (S)-2 and 4.
Consistently, novel hybrids were capable of inhibiting enzymatic
activity of recombinant human HDAC1 and 6, as measured by a
fluorimetric cell-free assay [16], to yield IC50 values that were
within a low micromolar range (Fig. 4C); the rank order of potency
was (S)-2  4  (R)-2 reflecting somewhat that observed in cell-
based assays.
(S)-2 triggers apoptosis in different cultured 
and primary AML cells: preliminary evidence 
for ROS-mediated cell death
Since (S)-2 exhibited the greatest HDACi activity and pro-apoptotic
potency in NB4 cells, its efficacy was explored further in different
AML cell lines. Cells were incubated with/out increasing (S)-2
concentrations for 48 hrs and then submitted to the Annexinn V/PI
assay to determine the amount of apoptotic cells within the 
population (Fig. 5A). Kasumi cells appeared to be especially sen-
sitive to the drug (IC50  0.61 M), followed by KG1a, HL-60,
NB4 and ATRA-resistant NB4-MR4 cells (IC50 within a range of
1.4–2.1 M) while U937 and THP-1 yielded values of 4.5 and 
6.5 M, respectively.
Pro-apoptotic effectiveness of (S)-2 over such a wide range of
different cultured AML cell lines prompted us to investigate on
action mechanisms of drug-induced apoptosis. Toward this aim,
NB4 cells were treated with/out 2 M (S)-2 for 15 hrs either in the
absence or in the presence of 15 mM anti-oxidant N-Acetyl
Fig. 3 (A-top) Cytofluorimetric analysis of apoptosis. NB4 cells were
treated without/with 2.5 M drugs for 48 hrs and incubated with
AnnexinV-Fluos in a HEPES buffer containing PI for 15 min.; the number of
apoptotic cells was then measured by flow cytometry (FACScan equip-
ment). X axis: % of apoptotic cells; Y axis: conditions of stimulation; bars
were the means 
 SD of three separate experiments. (A-bottom) Cell mor-
phology. Cytosmears of untreated and drug-treated NB4 cells as above
were stained with May-Grünwald/Giemsa. Pictures (magnification: 200)
were from a typical experiment out of three. Drug-induced PARP cleavage
(at 15 hrs, panel B) to yield a fragment of approximately 89 kD, and H2AX
phosphorylation (at 24 hrs, panel C) were observed by Western blot and
immunostaining; -tubulin was used as the reference protein.
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Cysteine (NAC) applied 2 hrs before adding the drug. As expected,
(S)-2 caused the cleavage of PARP resulting from activation of the
caspase cascade, and the appearance of -H2AX due to drug-
induced DNA damage. Both these events were inhibited by the
presence of NAC to highlight the major role of ROS in drug-medi-
ated cell death (Fig. 5B).
Pro-apoptotic properties of (S)-2 were also explored ex vivo in
cultured blasts from patients with different AML (M1–M4) sub-
types by using peripheral mononuclear blood cells (PBMCs) from
normal subjects as the control. Cells treated for 48 hrs with/out 1
and 2 M drug were collected, fixed and stained with May-
Grünwald/Giemsa. There was a dose-dependent increase in apop-
totic cells in cytosmears of all the treated AML samples; blasts of
M1 and M2 subtype seemed to be especially drug-sensitive, while
normal PMBCs were unaffected by the drug (Fig. 5C).
(S)-2 has a low-toxic profile in vivo
Normal CD-1 mice were used as the model for acute toxicity
experiments. Animals were injected i.p. only once with increasing
(S)-2 concentrations dissolved in 0.1 ml DMSO (see legend to 
Fig. 6A and Supporting Information, S3). All the mice displayed an
increase in weight and excellent survival rates within a week
despite the dosage. Moreover, the histopathology of bone marrow,
liver, spleen and kidney specimens from mice receiving either the
vehicle or the higher (S)-2 dosage (about 150 mg/Kg; i.e.
5 mg/mouse) revealed no specific drug-induced damage such as
cell loss, necrotic areas or other signs of acute toxicity relative to
controls (Fig. 6A). A slight vacuolization in liver and kidney
parenchimal cells of both treated and untreated mice was
observed and due, conceivably, to hypoxic conditions at sacrifice.
Notably, similar results were obtained by replacing (S)-2 with
comparable amounts of non-chiral compound 4 (data not shown).
(S)-2, (R)-2 and 4 show virtually no affinity 
for both CBR and PBR
Novel HDACi were tested in tissue extracts (Supporting
Information, S4) for their ability to bind CBR or PBR by using Ro
15–1788 and PK 11195 as the specific ligand, respectively, and
diazepam as the common ligand (Fig. 6B). At the two concentra-
tions used (S)-2, (R)-2 and 4 showed virtually no affinity for both
CBR and PBR as compared to the high affinity of Ro 15–1788 and
diazepam for CBR and of PK 11195 and diazepam for PBR. The
racemic BDZ cap (rac-7) due to its structural similarity to
diazepam and the lack of the hydroxamic moiety showed a partial
ability to bind both the receptors.
Fig. 4 Drug-induced acetylation of histone and nonhistone proteins in NB4
cells. (A) Cells were incubated for 6 hrs without/with 2 M (S)-2 or (R)-2 or
4, and then processed by Western blot and immunostained for acetylated
H3/H4; H3/H4 were the loading controls. Cell extracts were also analysed by
immunoblotting for (B) acetylated forms of nonhistone proteins -tubulin
and p53 after 6 and 24 hrs of treatment, respectively; -tubulin and p53 were
used as the reference proteins. (C) Drug-induced inhibition of human recom-
binant HDAC1 and HDAC6 activity was determined by a fluorimetric cell-free
assay (Supporting Information, S2); IC50 values were from a typical experi-
ment out of three.
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Fig. 5 (S)-2 triggers apoptosis in different
cultured and primary AML cells. (A) Different
AML cell lines were treated for 2 days without/
with increasing (S)-2 concentrations and
then submitted to the Annexinn V/PI assay to
determine the amount of apoptotic cells
within the population. IC50 values represent
the drug concentration (M) needed for
inducing 50% of cell population toward
apoptosis relative to control; values were the
means 
 SD of three separate experiments.
(B) Pro-apoptotic effects of (S)-2 in NB4
cells developed through the drug-mediated
generation of ROS. Activation of apoptosis
was revealed at 15 hrs, by the cleavage of
PARP and phosphorylation of H2AX protein;
and these events were efficiently contrasted
by 15 mM N-Acetyl Cysteine (NAC) applied 
2 hrs before drug addition; -tubulin was 
used as the reference protein. (C) Ex vivo
experiments on human different primary
AML cells. May-Grünwald/Giemsa stained
cytosmears of blasts (magnification: 200)
from peripheral blood of four newly diag-
Fig. 6 (A) (S)-2 is well tolerated in normal
CD-1 mice which have been used as the
model for acute toxicity experiments. Animals
were injected i.p. only once with increasing
(S)-2 concentrations dissolved in 0.1 ml DMSO
and sacrificed after a week (see Supporting
Information, S3). Pictures (magnification:
200) reported in this panel concern the
histopathology of organs explanted from
mice which were treated with the higher drug
dosage, i.e. 150 mg/kg, corresponding to
about 5 mg/mouse. No specific drug-induced
tissue alteration in treated versus mice
treated with the vehicle alone was observed.
Consecutive 2.5–5 m sections of samples
were stained with May-Grünwald/Giemsa and
examined under a bright field microscope
(Nikon Eclipse, mod. 50i) equipped with a
digital camera (DS-5M USB2) (Nikon
Instruments, Florence, Italy). (B) Binding
experiments in tissue extracts. The affinity of
novel HDACi, at the two concentrations used
(10 and 100 M, respectively) for CBR was
assayed by using membranes from rat cere-
bral cortex that were prepared as described
by Mehta and Shank [17], while for PBR, rat
kidney mitochondrial membrane prepara-
tions as described by Miccoli et al. were
employed [18]. Bars were the means 
 SE of
three separate experiments; for details see
Supporting Information, S4.
nosed AML patients with M1, M2, M3 and M4 subtypes after 48 hrs of treatment without/with 1 and 2 M drug. Peripheral blood mononuclear cells
(PBMCs) from normal donors have also been isolated and treated as above after a 12-hr stimulation with PHA (125 g/ml) and IL-2 (1 ng/ml).
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Discussion
The compounds reported in this study were chosen for their pecu-
liar chemico-biological properties: the strikingly high enantiose-
lectivity of (S)-2 relative to (R)-2, the eutomer being (S)-2 enan-
tiomer, and the interesting comparison between activities of chiral
(S)-2 and (R)-2 versus their non-chiral analogue 4.
The presence of a methyl group in position 3 on the BDZ
nucleus was not so important for biological HDACi activity as
(S)-2 and, to a lesser extent, 4 produced similar effects in 
NB4 cells and these were namely: (i ) G0/G1 cell cycle arrest, 
(ii ) acetylation of histone H3/H4 and nonhistone proteins, 
(iii ) cleavage of PARP and increased levels of -H2AX in
response to drug-induced DNA damage. Altogether, these
events led to a massive apoptosis that, on average, developed in
all the different cultured and primary AML cells reported herein,
within 2–3 days at low micromolar drug dosages. On the other
hand, the orientation of the chiral group on the BDZ ring
seemed to be crucial for determining how the cap interacts with
the external domain of HDACs within the intracellular milieu
and, eventually, conferring enantioselectivity; the (S) configura-
tion is preferred over the (R) one.
As regards nonhistone proteins, enhanced levels of acetylated
-tubulin and acetylated p53 were detected in Western blots of
cells treated with (S)-2 or 4 to suggest that HDAC6 and HDAC1,
respectively, were targeted by the two active HDACi, while (R)-2
produced just a minor signal. Partially consistent with this, all the
three hybrids were capable, albeit with different potency, of inhibit-
ing enzymatic activity of recombinant HDAC1 and HDAC6 thus
addressing these isoforms as sensitive targets of novel HDACi but
also emphasizing that results of fluorimetric cell-free assays do
not always necessarily reflect biological activities of a given HDACi
in cell-based assays.
The majority of biological assays reported herein pointed to
(S)-2 as the lead compound to be challenged in different cultured
and primary AML cells. It is worth noting that promyelocytic NB4
and NB4-MR4 cells despite their different genetic asset and
responsiveness to ATRA displayed similar IC50 values around 2
M; while U937 and THP1 showed two- to three-fold higher val-
ues. With regard to ex vivo conditions, (S)-2 triggered apoptosis
in blasts from patients with M1, M2, M3 and M4 AML subtype
[12] at 1–2 M dose, while normal PBMCs were virtually unaf-
fected by the treatment.
Importantly, the present study provides preliminary evidence
that pro-apoptotic effects of (S)-2 in NB4 cells develop through
the drug-mediated generation of ROS that induces DNA damage,
as denoted by the cleavage of PARP and increase in -H2AX 
levels. Both these events were effectively prevented by the addi-
tion of the antioxidant N-acetyl-cysteine.
The results presented in this work concern the activities of
novel HDACi used alone, well aware of the fact that their full anti-
cancer potential in the clinic will derive from combination therapy
with either standard anti-neoplastic agents or other experimental
chemotherapies [9, 24]. Moreover, any HDACi to be employed in
vivo should also be effective and safe. Regarding effectiveness,
(S)-2 displayed HDACi activities that were similar to those of
SAHA [11] and, in terms of safety, results of acute toxicity exper-
iments show that (S)-2 was well tolerated in CD-1 mice up to very
high dosage.
Overall, our findings have proven the powerful cytostatic and
pro-apoptotic properties of the novel BDZ-hydroxamate (S)-2 in
different cultured and primary AML cells as well as its low-toxic
profile in vivo, and pointed to this drug as a useful epigenetic tool
to support standard therapy for the treatment of AML and, possi-
bly, other types of haematological and solid malignancies.
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